Powerful Technology Developed to Combat Mosquito-Borne Diseases, Including Malaria and West Nile, Receives Grant from National Institutes of Health

Olfactor Laboratories, Inc. receives Federal research grant to further technology proven to inhibit mosquitos' ability to seek humans.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We’re developing products based on our technology, that I believe, will have true global impact. There is nothing more important our company can be doing at this time,” said Dr. Brown.

Riverside, CA (PRWEB) April 15, 2013

Olfactor Laboratories, Inc. (OLI), an ieCrowd venture, was awarded a research grant from the United States National Institutes for Health (NIH), for the further development of OLI’s breakthrough technology proven to inhibit a mosquito’s ability to seek humans and animals by disrupting the insect’s CO2 receptors.

The OLI science team, led by Dr. Michelle Brown, will be using the grant funding to determine which of the CO2 receptor effector molecules in OLI’s proprietary and patent pending portfolio of non-toxic and non-insecticidal compounds best disrupt the host-seeking behavior of mosquitos.

According to the World Health Organization, over 3.3 billion people live in Malaria-affected regions and it remains one of the most deadly mosquito-borne diseases in the world. Stephen Abbott, President of Managed Innovations for Innovation Economy, cited this award as an opportunity to use the unique OLI research facility in Riverside, CA – an indoor mosquito behavior testing lab - to further refine OLI’s products being developed for worldwide distribution. “It’s a great boost for a critical technology,” said Abbott.

“With technology this powerful, we’re happy to begin a partnership with NIH in advancing our field testing and research. We’re developing products based on our technology, that I believe, will have true global impact. There is nothing more important our company can be doing at this time,” said Dr. Brown.    

About Olfactor Laboratories, Inc. (OLI). OLI is developing a novel class of spatial, non-insecticidal compounds that manipulate certain blood-feeding insects’ primary mechanism used in locating their prey. Blood-feeding insects such as mosquitoes, which spread Malaria, dengue and filariasis, track their prey through carbon dioxide (CO2) emissions in breath using their olfactory neurons (sense of smell).

About ieCrowd. Located in Riverside, California, ieCrowd’s mission is to acquire innovative research, technology, products and services and transform them into high-growth ventures with global impact potential. ieCrowd.com is the company's new crowd-powered platform, currently in phase one of its roll-out, which is designed to enable everyone to participate in the social and economic opportunities created by developing and growing innovative businesses.


Contact

Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn

Attachments